Oncology Central and Future Oncology: top content from 2020
This article takes a look back at some of the top content over the last year published by Oncology Central and our associated journal, Future Oncology.
This article takes a look back at some of the top content over the last year published by Oncology Central and our associated journal, Future Oncology.
OPTYX is a multi-center, prospective, observational study designed to further understand the actual experience of patients with advanced prostate cancer treated with relugolix (ORGOVYX®), an…
What challenges are associated with value-based oncology care and how can these be overcome?
Discover the strides being made to unravel the complexities of brain tumors in our latest interview with Karen Noble.
What challenges are associated with value-based oncology care and how can these be overcome?
Explore opportunities for women in neuro-oncology with Dr Macarena Ines De La Fuente who has been the co-chair of the SNO’s Women and Diversity Committee.
How can MRI-guided radiation therapy offer in terms of real-time insights into glioblastoma disease progression?
What challenges are associated with value-based oncology care and how can these be overcome?
Neuregulin 1 (NRG1) fusions are oncogenic drivers that have been detected in non-small-cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. NRG1…
eNRGy is a clinical trial of zenocutuzumab for cancer caused by NRG1 gene fusions. Find out more in our latest journal feature here.
What are the latest developments in diagnostic and therapeutic options for pancreatic cancer patients? Find out in our interview with Mandana Kamgar